TY - JOUR
T1 - Ophthalmic drug discovery
AU - Clark, Abbot F.
AU - Yorio, Thomas
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/6
Y1 - 2003/6
N2 - Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.
AB - Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.
UR - http://www.scopus.com/inward/record.url?scp=0038132019&partnerID=8YFLogxK
U2 - 10.1038/nrd1106
DO - 10.1038/nrd1106
M3 - Review article
C2 - 12776220
AN - SCOPUS:0038132019
SN - 1474-1776
VL - 2
SP - 448
EP - 459
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 6
ER -